Compare Stocks

The First Trust RBA American Industrial RenaissanceTM ETF (AIRR) is an exchange-traded fund that mostly invests in industrials equity. The fund tracks a multifactor-selected index of equities that can benefit from potential regain in market share of US industrial and community banking sector. AIRR was launched on Mar 10, 2014 and is managed by First Trust.

The iShares USD Green Bond ETF (BGRN) is an exchange-traded fund that mostly invests in investment grade fixed income. The fund tracks a market-value-weighted index of USD-denominated investment-grade government and corporate bonds linked to environmentally beneficial projects, as identified by MSCI. BGRN was launched on Nov 13, 2018 and is managed by BlackRock.

The First Trust Emerging Markets Local Currency Bond ETF (FEMB) is an exchange-traded fund that mostly invests in broad credit fixed income. The fund is an actively managed fund that invests in a broad range of bonds issued by emerging-market sovereign, sub-sovereign and quasi-sovereign entities, denominated in local currencies. FEMB was launched on Nov 4, 2014 and is managed by First Trust.

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.